All In Biotech

Drug Trial Radar · NCT00117754

Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

Last checked: Nov 19, 2026Latest source record: Feb 21, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

720

Actual

Start

Jul 2004

Primary completion

Not stated

Study completion Apr 2006

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Jul 8, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Single
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum. Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis.

Conditions

  • Tinea Capitis

Interventions

  • Terbinafine hydrochlorideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete cure (negative mycology and clinical cure) rate at Week 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis Pharmaceuticals

    East Hanover, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.